EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Systemic Treatment of Breast Cancer

Sara Alsterlind Hurvitz

New England Journal of Medicine · 2026

DOI: 10.1056/nejmra2500695 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift New England Journal of Medicine, 2026. Verfasst von Sara Alsterlind Hurvitz. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Molecular Targeted Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic therapy for breast cancer has evolved rapidly since 2020, driven by the expansion of targeted therapies, antibody-drug conjugates, and immunotherapy across biologic subtypes. The integration of tumor molecular profiling and germline testing has enabled increasingly personalized, biomarker-guided treatment strategies. In hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative disease, cyclin-dependent kinase 4 and 6 inhibitors remain foundational, whereas phosphatidylinositol 3-kinase pathway inhibitors, oral selective estrogen-receptor degraders, and antibody-drug conjugates have transformed disease management after endocrine resistance. In HER2-positive disease, antibody-drug conjugates - particularly trastuzumab deruxtecan - have improved outcomes and are being used in earlier lines of therapy, a development that is reshaping treatment paradigms. In triple-negative breast cancer, immune checkpoint inhibitors have improved outcomes in both metastatic and early-stage disease. Across subtypes, advances in curative therapy increasingly emphasize risk-adapted escalation and de-escalation of treatment. Ongoing challenges include improving treatment sequencing, identifying predictive biomarkers, integrating emerging tools such as analysis of circulating tumor DNA, and ensuring equitable access to high-cost therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsMolecular Targeted TherapyAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesImmunoconjugatesPrecision MedicineImmune Checkpoint InhibitorsCirculating Tumor DNANeoplasm StagingProtein Kinase InhibitorsReceptors, EstrogenReceptors, ProgesteroneAntineoplastic Agents, HormonalClass I Phosphatidylinositol 3-KinasesProgression-Free SurvivalNeoadjuvant TherapyChemotherapy, Adjuvant

Substanzen

Antineoplastic AgentsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesImmunoconjugatesImmune Checkpoint InhibitorsCirculating Tumor DNAProtein Kinase InhibitorsERBB2 protein, humanReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle.

Zitieren

APA

Hurvitz, S. A. (2026). Advances in Systemic Treatment of Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmra2500695

Vancouver

Hurvitz SA. Advances in Systemic Treatment of Breast Cancer. New England Journal of Medicine. 2026. doi:10.1056/nejmra2500695

BibTeX
@article{Hurvitz2026,
  author = {Hurvitz, Sara Alsterlind},
  title = {Advances in Systemic Treatment of Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmra2500695}
}
Kostenlos starten →